Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...